1. INTRODUCTION
===============

Vascular and neurodegenerative disorders are among the most prevalent causes of death in Western Countries. The knowledge of the human genome allows the detection of modifications in the sequence of certain genes responsible for a number of these diseases. The appropriate genetic counseling relies on the characterization of these risk polymorphisms for accurate individual or family decision making.

Metabolic Syndrome (MS) affects 20-34% of the population \[[@r1], [@r2]\], primarily in the developed countries. Definition of MS slightly differs depending on the source \[[@r3]-[@r5]\], although it is generally defined by the confluence of several medical conditions, including low high-density lipoprotein (HDL) levels, high blood serum triglycerides, high blood pressure, abdominal obesity, and elevated fasting plasma glucose. Individuals with MS are more likely candidates to develop cerebrovascular and cardiovascular disease and diabetes than the general population.

Cerebrovascular disorders and stroke are the third leading cause of death in the US and in Europe with around 200 cases per 100,000 inhabitants per year \[[@r6]\] and almost six million victims every year, according to the World Health Organization \[[@r7]\]. Cerebrovascular disorders are characterized by the blockade of arterial vascularization (atherosclerosis) with the consequent deprivation of oxygen and glucose supply to the affected tissue, leading to cell death and tissue necrosis or ischemia. Depending on the anatomical site of the ischemic insult, cerebral stroke can lead to hemiplegia, aphasia, motor dysfunction, or dementia. Atherosclerosis is a form of chronic inflammation resulting from the interaction of different factors, including enhanced uptake of low-density lipoprotein (LDL) by monocytes and macrophages \[[@r8], [@r9]\], immune response, and development of plaque deposits in the lumen of the blood vessels \[[@r10], [@r11]\]. Several genetic risk markers involved in the atherosclerosis-related pathways have been identified \[[@r12]\].

Certain polymorphisms in genes encoding apolipoproteins (*APOB, APOC3, APOE*) and the cholesterol ester transfer protein (*CTEP*) are associated with an aberrant increase in LDL-family lipoproteins, cholesterol, and triglyceride levels. Therefore, these gene variants are involved in the risk for atherosclerosis and vascular disorders \[[@r13]-[@r20]\]. However, the polymorphism C1421G (rs328) in the *LPL* gene, coding for the lipoprotein lipase, develops a protective effect by increasing the levels of high density lipoproteins (HDL) and decreasing the triglycerides \[[@r13], [@r21], [@r22]\]. One of the signs of the progression from the initial fatty streak to the more complex lesions in the artery wall is the high blood pressure. Specific polymorphisms in *NOS3, ACE*, and *AGT*, involved in endothelial function and regulation of blood pressure, are indicative of the progression of the atherosclerotic plaque \[[@r13], [@r23]-[@r27]\]. The role of inflammation in atherosclerosis is well established \[[@r11]\], as well as its implication in thrombosis by enhancing the coagulation process \[[@r28]\]. In this regard, polymorphisms in genes encoding proinflammatory interleukins, especially *IL1* and *IL6*, promote their expression leading to atherothrombosis and lacunar infarction \[[@r13], [@r29]-[@r34]\]. The variant -308G\>A (rs1800629) in the tumor necrosis factor gene (*TNFA*) has also been observed to be associated with migraine, which suggests the role of this polymorphism in the regulation of blood flow throughout the brain \[[@r35]\]. Although the progressive narrowing of the blood vessel during the atherosclerotic process can develop ischemic symptoms, stroke is normally promoted by the rupture of the sclerotic plaque and thrombosis. Polymorphisms in the genes coding the coagulation factors F2 and F5 are associated with the accumulation of prothrombin, increasing the risk of thrombosis \[[@r13], [@r36]-[@r38]\]. The *MTHFR* gene encodes for the methylentetrahydrofolate reductase which remethylates homocysteine into methionine. The polymorphisms 1298A\>C (rs1801131) and 677C\>T (rs1801133) in *MTHFR* result in the accumulation of homocysteine in plasma and increase the risk of a premature cardiovascular disorder up to three times compared to the general population \[[@r39], [@r40]\].

According to the World Health Organization (WHO), cerebrovascular and neurodegenerative disorders affect one billion people around the world. A number of these disorders are characterized by the onset of dementia. Disability caused by dementia increases dramatically with aging, by affecting 9 per 1000 of the population aged 65-74 years to 83 per 1000 in the population over 85 years old \[[@r41]\]. Alzheimer's disease (AD) is the major cause of dementia in Western Countries, affecting 45-60% of the population, followed by vascular dementia and mixed dementia with prevalences of 30-40% and 10-20%, respectively \[[@r42], [@r43]\]. AD is a polygenic and complex disorder characterized by the accumulation of β-amyloid (Aβ) in senile plaques, neurofibrillary tangles, dendritic desarborization, and neuronal loss, which leads to memory deterioration, dementia, and functional decline \[[@r42]-[@r44]\].

The *PSEN1* and *PSEN2* genes, encoding presenilin1 and 2, are important determinants of the β-secretase activity responsible for proteolytic cleavage of the Aβ-precursor protein (APP). Mutations in the *PSEN1*, *PSEN2*, and *APP* confer phenotypes of amyloidogenic pathology and dementia \[[@r19], [@r42], 43, [@r45]\]. One of the most prevalent risk genes in AD is the *APOE*, especially in those individuals harboring the *APOE-ε4* allele \[[@r13], [@r19], 44, [@r46]\]. Interestingly, the allele *APOE-ε2*, which is associated with vascular risk, seems to be protective against dementia \[[@r13], [@r19], [@r44]\]. The *A2M* gene, encoding for the alpha-2-macroglobulin (a protease inhibitor), is also localized in amyloid plaques and interacts with Aβ and APOE. The polymorphism 2998G\>A (rs669) in homozygosis increases the risk for the onset of AD by 4-fold when compared to the general population \[[@r13], [@r19], [@r45]\].

We characterized risk polymorphisms of genes related to obesity, cardiovascular disorders, and dementia in 4415 individuals from Spain. This population included a high rate of individuals diagnosed with vascular-related disorders (25%), and with dementia-related diseases (15%). The other 55% of the population was diagnosed with other pathologies that might be indirectly related to vascular or neurodegenerative disorders. We aimed to characterize which risk polymorphisms were predominant in our population and found that polymorphisms in *ACE*, *AGT(235)*, *IL6(573)*, *PSEN1*, and *APOE* (especially the *APOE-ε4* allele) were representative of our population as compared to reference data from Spanish and European individuals. The significantly high rate of the polymorphism +16G\>T (rs165932) in the *PSEN1* gene, along with the high representation of the *APOE-ε4* allele, strongly suggests the presence of a significantly large group of individuals with potential AD disease onset in this population. The large number of individuals analyzed in this study may provide the main representative polymorphisms associated with risk for vascular disorders and dementia in the Spanish population.

2. MATERIALS AND METHODS
========================

2.1. Subjects
-------------

Risk polymorphisms were analyzed in a population of 4415 individuals from Spain (72% from Galicia and Northern Spanish regions, and the remaining 18% from a widespread Spanish distribution) attending the outpatient clinic at the EuroEspes Biomedical Research Center from January 1995 to December 2015. The individuals were equally distributed in terms of gender, being 48.15% males and 51.85% females. Table **[1](#T1){ref-type="table"}** shows the distribution of the population according to age-range and diagnosis. The most representative age ranges were 30-60 years old (43%) and older than 60 (37%), whereas only 20% of individuals were younger than 30 years old. A representative number of those individuals (25%) were diagnosed with disorders associated with vascular damage or vascular risk, such as metabolic syndrome, brain trauma, cerebral stroke, epilepsy, cephalea. A total of 15% of individuals were diagnosed with dementia-related disorders, including AD, and vascular and mixed dementias; these last two being the most representative ones. Among neurodegenerative disorders, besides AD, approximately 4% of individuals were diagnosed with Parkinson's disease. Over 26% carried psychiatric disorders, including stress-anxiety and depression. The last 30% of patients were diagnosed with peripheral nervous system disorders and other pathologies (Table **[1](#T1){ref-type="table"}**).

2.2. Genotype Analysis
----------------------

Blood was extracted in EDTA-coated tubes and DNA from peripheral blood was extracted using the Qiagen DNA Blood Minikit (Qiagen, Hilden, Germany). A total of 20 different genes were genotyped (Table **[2](#T2){ref-type="table"}**) by Real Time PCR (RT-PCR) using TaqMan assays designed for single nucleotide polymorphisms (SNPs). RT-PCRs were performed in Step One Plus Real Time PCR System (Life Technologies, Waltham, Massachusetts, USA), and TaqMan^®^ Open Array^®^ DNA microchips in Quant Studio^TM^ 12K Flex RT-PCR System (Life Technologies, Waltham, Massachusetts, USA). Open Array^®^ genotyping analyses were performed using the Genotyper software provided by Thermo Fisher Scientific, Waltham, Massachusetts, USA.

2.3. Statistical Analysis
-------------------------

Deviation from Hardy-Weinberg equilibrium (HWE) was analyzed by a chi-square test (χ^2^). Genotype distribution was considered in HWE when observed and theoretical distribution was similar with a P\>0.05. The comparison of genotype frequencies in our population with others was analyzed using the Pearson's chi-square test, considering an equal genotype distribution when the two populations showed a similar distribution with a P\>0.05.

2.4. Patient Consent
--------------------

Written informed consent was obtained from all participants, or from a legal caregiver or representative on their behalf in case of incapability. This study and the consent procedures were approved by the institutional review board at the EuroEspes Medical Center, in line with the ethical code of the World Medical Association (Declaration of Helsinki) and the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journals Editors (ICMJE).

3. Results
==========

3.1. Polymorphisms in *ACE, AGT-235, IL6-573*, and *PSEN1* were Significantly More Represented in Our Population Compared to Representative Spanish and European Populations
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Polymorphisms in a total of 20 selected genes associated with vascular risk and dementia-related neurodegeneration were analyzed. Gene polymorphisms were selected into panels according to i) previous research \[[@r47]\] and ii) genotyping in over 4000 patients. Genes were then classified into risk panels, defined as groups of genes and gene polymorphisms involved in the different steps (subpanels) which lead to the atherogenic process. In this regard, gene polymorphisms were classified into *Obesity*, *Vascular Risk*, and *Neurodegeneration* panels, and subpanels including *Lipid Metabolism, Endothelial Function, Hypertension, Immune Response*, and *Thrombosis* (Table **[2](#T2){ref-type="table"}**). Allele and genotype frequencies were calculated for each gene polymorphism. Risk alleles and their corresponding risk genotypes in homozygosis are in bold Table **[2](#T2){ref-type="table"}**.

A total of 8 out of the 20 polymorphism genotype distributions analyzed were not in Hardy-Weinberg equilibrium (HWE), these including *LPL* (χ^2^=34.29; d.f.=2), *ACE* (χ^2^=48.20; d.f.=2), *AGT174* (χ^2^=9.37; d.f.=2), *AGT235* (χ^2^=157.41; d.f.=2), *IL1B* (χ^2^=4.88; d.f.=2), *IL6(174)* (χ^2^=6.18; d.f.=2), *IL6(573)* (χ^2^=76.31; d.f.=2), and *PSEN1* (χ^2^=79.56; d.f.=2). Importantly, each polymorphism was analyzed in more than 900 patients (Table **[2](#T2){ref-type="table"}**), which rules out the possibility of a non-representative sample size. This finding suggested that those genes might be biased in our population, most probably due to the variety of vascular risk and dementia phenotypes in our patients.

Fig. (**[1](#F1){ref-type="fig"}**) plots the risk allele frequencies of these polymorphisms outside HWE in our population (EuroEspes, black bars) with a differential distribution by comparison with other European populations, and especially with other Spanish groups (Mixed European: 1006 individuals; Spanish: 107 individuals; Italians: 107 individuals; British: 91 individuals; Finnish: 99 individuals. These data were extracted from "dbSNP" \[[@r48]\] and "1000 Genomes" \[[@r49]\] databases). In addition, polymorphisms in *APOC3* and *A2M*, which did not deviate from HWE in our population, also showed a differential risk allele frequency distribution when compared to another representative Spanish population (Fig. **[1](#F1){ref-type="fig"}**). We used Pearson's chi-square test to assess whether the genotype distribution of the above mentioned genes in our population was significantly different from other representative European populations which do not deviate from HWE (Table **[3](#T3){ref-type="table"}**). The genes with a significant genotype distribution in our patients compared to representative Spanish populations were *ACE* (χ^2^=9.49; P\<0.01), *AGT-235* (χ^2^=17.04; P\<0.001), *IL6-573* (χ^2^=10.99; P\<0.005), and *PSEN1* (χ^2^=13.59; P\<0.0025) (Table **[3](#T3){ref-type="table"}**). Indeed, the genotype distribution of *IL6-573* and *PSEN1* in our population significantly differed from all the other European populations tested (P\<0.05), whereas those distributions of *AGT-235* and *ACE* show similarities with a few other European populations (Table **[3](#T3){ref-type="table"}**).

Populations: 1324 healthy individuals with a Northern and Western European ancestry extracted from the HapMap-CEU and Parc European studies \[[@r48]\]; and 99, 91, 107, and 107 healthy individuals from Finland, Britain, Spain, and Italy, respectively, extracted from the 1000 Genomes database \[[@r49]\].

3.2. The *APOE-ε4* Allele is Highly Represented in Our Study Population
-----------------------------------------------------------------------

When comparing the distribution of all *APOE* alleles around the world, *APOE-ε3* is the most predominant with frequencies of 0.76 ± 0.09, followed by *APOE-ε4* (0.13 ± 0.07), and *APOE-ε2* (0.06 ± 0.02) \[[@r13]\]. It has been widely reported that the most prevalent risk factor for AD is an increased *APOE-ε4* distribution (0.36 ± 0.07) and decreased *APOE-ε2* (0.03 ± 0.02) \[[@r13], [@r19], 44, [@r46]\]. Allele distribution for *APOE* in our study population was apparently among the usual in general European populations \[[@r13]\]: *APOE-ε3*=0.815, *APOE-ε4*=0.135, and

*APOE-ε2*=0.050 (Table **[2](#T2){ref-type="table"}**). Indeed, despite the representative number of individuals with vascular risk and dementia in our group, distribution of *APOE-ε2* and *APOE-ε4* appeared within the range of those of other European and Worldwide populations \[[@r50]-[@r67]\] (Fig. **[2](#F2){ref-type="fig"}**). It is widely documented that the *APOE-ε4* allele rate is lower in Spanish and South European populations \[[@r50], [@r64]-[@r67]\], but the levels of *APOE-ε4* in our study population are rather higher than those of South Europeans, including Spanish individuals (Fig. **[2](#F2){ref-type="fig"}**), which, once again, might be related to the rate of dementia and atherosclerosis risk in our group. *APOE-ε2* distribution is also slightly lower in our population compared to all the other groups, although still far from those with AD (grey bars, Fig. **[2](#F2){ref-type="fig"}**).

In order to establish the influence of *APOE-ε4* and *APOE-ε2* distribution in our population, we performed a comparative analysis of the *APOE* genotype variants with other representative Spanish populations \[[@r51], [@r52], 54, 56, 58, 61, 63-[@r67]\] (Fig. **[3A](#F3){ref-type="fig"}**). *APOE* genotypes containing the alleles *ε2* and *ε3* (*ε2/ε2*, *ε2/ε3*, and *ε3/ε3*) did not display large differences between our population and average Spanish groups. However, genotypes containing the *ε4* allele were much more evident in our population, especially the homozygous *ε4/ε4*, with a 2.5-fold increase, followed by the heterozygous *ε2/ε4*, with a near 2-fold increase, and *ε3/ε4* showing an approximately 1.5-fold increase (Fig. **[3B](#F3){ref-type="fig"}**). Pearson's chi-square test provided evidence of a significantly different distribution of the *APOE* genotypes in our population as compared to five separate representative Spanish populations (P\<0.01-0.001) (Table **[4](#T4){ref-type="table"}**), which strongly suggests the high influence of the *APOE-ε4* allele in our population. Those particularly higher levels of *APOE-ε4* and *PSEN1* may be a sign of a representative number of individuals with AD in our group. Nevertheless, the *APOE-ε4* rate in our group still far differs from Spanish individuals with AD (P\<0.001) Table **[4](#T4){ref-type="table"}**. Although *APOE* genotypes involving the *ε4* allele (*ε4/ε4*, *ε2/ε4*, and *ε3/ε4*) are significantly higher in our population compared to other Spanish groups, it is nevertheless sited within the range values of average European and Worldwide populations, unlike the *ε2/ε2* genotype (Fig. **[4](#F4){ref-type="fig"}**).

4. DISCUSSION
=============

This study evaluates the impact of 20 gene polymorphisms associated with vascular risk and dementia (Table **[2](#T2){ref-type="table"}**) in a broad population of 4415 individuals from Spain carrying a variety of disorders involving metabolic syndrome, vascular damage, and impaired cognitive decline leading to dementia, among others Table **[1](#T1){ref-type="table"}**. A total of approximately 40% of patients were diagnosed with disorders involving, directly or indirectly, vascular damage or cognitive decline leading to dementia. A significant part of those patients with dementia have a cerebrovascular component. Some of the remaining 60% of pathologies (psychiatric disorders, peripheral nervous system (PNS) impairment, or others) might also lead to vascular damage or dementia, depending on the disease progression or genetic predisposition of the individuals.

Genotype distributions in 8 out of the 20 polymorphisms analyzed (*LPL, ACE, AGT-174, AGT-235, IL1B, IL6-174, IL6-573, PSEN1*) deviate from HWE Table **[2](#T2){ref-type="table"}**. In this case, the number of individuals analyzed was large enough to be representative. Therefore, those gene polymorphisms were good candidates to distinguish our biased group from average populations. However, when the genotype distribution of these genes in our group was compared with other representative Spanish or European populations, we found that only the polymorphisms *ACE* (547C\>T, rs4332), *AGT* (9543A\>G, M235T, rs699), *IL6* (573G\>C, rs1800796), and *PSEN1* (16G\>T, rs165932) were representative in our population (Fig. **[1](#F1){ref-type="fig"}**; Table **[3](#T3){ref-type="table"}**).

Hypertension is one of the leading risks (50-70%) for cardiovascular disorders and cerebral stroke, which are considered to be among the top three causes of death in the US and Europe \[[@r6], [@r7]\]. Polymorphisms in genes involved in blood pressure regulation are markedly represented in our population. Genes encoding for angiotensin I-converting enzyme (*ACE*) and the angiotensinogen (*AGT*) are involved in the renin-angiotensin system pathway that regulates blood pressure. Polymorphisms in those genes have been reported to be associated with hypertension \[[@r13], [@r24]-[@r27]\]. Polymorphisms in inflammation-related genes such as *IL6* are also involved in hypertension and atherosclerosis \[[@r11], [@r13], 28, 31, [@r33]\], although the physiological mechanisms are not well characterized.

Apparently, hypertension-related polymorphisms, rather than lipid metabolism-related variations, are the major genetic cause for vascular disorders in our population. Indeed, correlation studies performed in Spanish populations demonstrate that regions with a higher total fat consumption presented a lower coronary-leading mortality, and vice versa \[[@r68], [@r69]\]. This finding suggests (i) the strong influence of genetic predisposition over environmental factors; (ii) the lower importance of variations in genes involved in lipid metabolism (*APOB, APOC3, CETP*) compared to those involving blood pressure regulation in Spanish populations.

The only gene involved in lipid metabolism with a representative influence in our population was *APOE*, and particularly, the *APOE-ε4* allele (Figs. **2-4**, Table **[4](#T4){ref-type="table"}**). It is widely reported that the increased risk of developing an ischemic cardiopathy, which is directly proportional to the *APOE-ε4* allele frequency, follows a north-south gradient throughout Europe, being more frequent in northern than southern countries \[[@r50], [@r64]-67, 70, [@r71]\]. Although the *APOE-ε4* allele frequency in our population fitted within the range of European individuals, it was nevertheless higher than the average Spanish and South European populations (Fig. **[2](#F2){ref-type="fig"}**). In addition, all genotype variants involving *APOE-ε4* were predominant in our population compared to other Spanish groups (Fig. **[3](#F3){ref-type="fig"}**, Table **[4](#T4){ref-type="table"}**), but not to other Europeans or Worldwide populations (Fig. **[4](#F4){ref-type="fig"}**).

*APOE-ε4*, and especially the *APOE-ε4/ε4* genotype, is one of the most prevalent risk factors associated with neurological hallmarks of AD \[[@r13], [@r19], 44, [@r46]\]. It has been reported that *APOE-ε4* may influence AD by interacting with APP metabolism and Aβ accumulation, enhancing the hyperphosphorylation of tau protein, and starting a chain reaction involving oxidative processes, modification of the neuroimmunotrophic activity, altering lipid metabolism and transport, and membrane biosynthesis in sprouting and synaptic remodeling, and inducing apoptosis \[[@r13], [@r19], 44, 72-[@r74]\].

However, other different reasons may also explain the high rate of *APOE-ε4*, and the *APOE-ε4/ε4* genotype in our population. The *APOE-ε4* allele is highly associated with an aberrant increase in LDL-family lipoproteins and cholesterol, which promotes the risk of developing atherosclerosis and vascular disorders \[[@r13]-[@r20]\], which may be explained by the significant rate of disorders with a vascular component represented in our population. Some of the individuals belonging to the 15% carrying dementia-related disorders were diagnosed with AD, although a high proportion of them had a vascular component rather than neurodegenerative. In addition, *APOE*-related pathogenic mechanisms are also associated with brain aging \[[@r75]\], and over 35% of individuals in our population were older than 60.

The presence of *APOE-ε4* is a hallmark but not enough to cause AD. Nevertheless, besides the prevalence of *APOE-ε4*, there are also other good reasons to suggest that our population may have a higher rate of individuals with a potential onset of AD than previously expected: (i) Polymorphism +16G\>T (rs165932) in the *PSEN1* gene is also prevalent in our population compared to other representative Spanish and European populations (Table **[3](#T3){ref-type="table"}**). This polymorphism is a hallmark of AD, since it affects β-secretase activity leading to accumulation of Aβ \[[@r19], [@r42], 43, [@r45]\]. (ii) Contrary to *APOE-ε4*, carriers of *APOE-ε2* may be protected against dementia, and in fact, *APOE-ε2* allele distribution is usually lower in individuals with AD \[[@r13], [@r19], [@r44]\]. Our population displays a higher rate of *APOE-ε4* and lower *APOE-ε2* than other Spanish and South European populations (Figs. **2**,**3**). (iii) Several reports associate metabolic syndrome and diabetes as promoters of future AD onset \[[@r76]-[@r78]\], which would suggest a prognosis for a potential number of individuals in our population. However, some of those reports define as AD cases of dementia associated with a vascular component turning into neurodegeneration, which is not entirely correct.

CONCLUSION
==========

The objective of this study was to characterize the influence of gene polymorphisms related to vascular risk and dementia on a broad population of Spanish individuals diagnosed with a variety of disorders concerning impaired lipid metabolism, hypertension, atherosclerosis, and dementia, among others. Polymorphisms in *ACE*, *AGT(235)*, *IL6(573)*, *PSEN1*, and *APOE* (especially the *APOE-ε4* allele) were representative of our study population as compared to reference data of Spanish and European individuals. Results obtained in this work may yield the following conclusions: (i) the large number of individuals analyzed in this study might provide a hallmark of cardiovascular and dementia risk polymorphisms in the Spanish population; (ii) polymorphisms involving hypercholesterolemia are more pronounced in our population, rather than those related to lipid metabolism; (iii) the prevalence of *APOE-ε4* and +16G\>T (rs165932) variation in the *PSEN1* gene suggests a higher potential rate of AD onset in our population. Thus, AD diagnosis might be underestimated in our population, or not yet diagnosed since the classic symptoms had not yet shown up, although they might already be genetically imprinted.

Identification of risk polymorphisms provides information about the susceptibility of an individual for the onset of certain diseases, compared to the average population. A proper risk assessment requires the analysis of variations in multiple potential interacting genes at individual, family, and ethnical levels. Identification and proper analysis of risk polymorphisms will ensure more reliable, accurate, and affordable treatments.
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###### 

Description of the population characterized in this study: 4415 patients distributed throughout Spain (48.15% males and 51.85% females) who attended the outpatient clinic at the EuroEspes Biomedical Research Center (Spain) from January 1995 to December 2015.

  -------------------------------------------------------------------------------
  **Age Range**   **Age Rate (%)**   **Disease**           **Disease Rate (%)**
  --------------- ------------------ --------------------- ----------------------
  0-15            7.18               Cephalea              9.33

  16-30           13.16              Stress-Anxiety        18.10

  30-60           43.10              Depression            8.18

  \>60            36.56              Dementia (AD,VD,MD)   14.75

  \_\_            \_\_               Parkinson\'s          3.94

  \_\_            \_\_               Cerebral Stroke       9.99

  \_\_            \_\_               Epilepsy              4.01

  \_\_            \_\_               PNS Disorders         1.18

  \_\_            \_\_               Brain Trauma          0.45

  \_\_            \_\_               Metabolic\            0.68
                                     Syndrome              

  \_\_            \_\_               Others                29.40
  -------------------------------------------------------------------------------

AD: Alzheimer's Disease; VD: Vascular Dementia; MD: Mixed Dementia; PNS Disorders: Peripheral Nervous System Disorders.

###### 

Allelic and genotype frequencies of different gene polymorphisms associated with obesity, vascular and cardiovascular risk, and neurodegeneration.

  **Panel \[Subpanel\]**                                                                 **Gene**        **OMIM**   **Locus**   **Polymorphism**                                 **Risk SNP**                    **N**   **Allele Freq**                       **Genotype Freq**                                                                                     **H-W**
  -------------------------------------------------------------------------------------- --------------- ---------- ----------- ------------------------------------------------ ------------------------------- ------- ------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------
  \-**Obesity** -**Vascular Risk** \[Lipid Metabolism\]                                  *APOB*          107730     2p24p23     rs693 \[7545C\>T\]                               7545T                           931     C = 0.565 **T = 0.435**               CC = 0.319 CT = 0.492 **TT = 0.189**                                                                  Yes (P=0.65-0.7)
  \-**Obesity** -**Vascular Risk** \[Lipid Metabolism\]                                  *APOC3*         107720     11q23.3     rs5128 \[3175G\>C, S1/S2\]                       3175G                           932     C = 0.906 G = 0.094                   CC = 0.821 CG = 0.170 **GG = 0.009**                                                                  Yes (P=0.09-0.1)
  \-**Obesity** -**Vascular Risk** -**Neurodegeneration** \[Lipid Metabolism\]           *APOE*          107741     19q13.2     rs429358/rs7412 \[112T\>C/158T\>C\] E2, E3, E4   112T/158T (E2) 112C/158C (E4)   4377    ε3 = 0.815 **ε2 = 0.05 ε4 = 0.135**   ε 3 ε 3 = 0.668 ε 2 ε 3 = 0.079 ε 2 ε 4 = 0.014 ε 3 ε 4 = 0.212 **ε 2 ε 2 = 0.002 ε 4 ε 4 = 0.022**   Yes (P=0.35-0.4)
  \-**Obesity** -**Vascular Risk** \[Lipid Metabolism\]                                  *CETP*          118460     16q21       rs708272 \[+279G\>A, B1/B2\]                     +279G (B1)                      2006    A = 0.377 **G = 0.623**               AA = 0.142 AG = 0.47 **GG = 0.388**                                                                   Yes (P=0.1-0.15)
  \-**Obesity** -**Vascular Risk** \[Lipid Metabolism\]                                  *LPL*           609708     8p22        rs328 \[1421C\>G, S474X\]                        1421G (Protective)              931     C = 0.851 **G = 0.149**               CC = 0.724 CG = 0.254 **GG = 0.022**                                                                  No (P\<0.001)
  \-**Vascular Risk** -**Neurodegeneration** \[Endothelial Function\] \[Hypertension\]   *NOS3*          163729     7q36        rs1799983 \[894G\>T\]                            894T                            2711    G = 0.621 **T = 0.379**               GG = 0.386 GT = 0.471 **TT = 0.144**                                                                  Yes (P=0.25-0.3)
  \-**Vascular Risk** -**Neurodegeneration** \[Endothelial Function\] \[Hypertension\]   *ACE*           106180     17q23.3     rs4332 \[547C\>T\]                               547T                            954     C = 0.342 **T = 0.658**               CC = 0.117 CT = 0.450 **TT = 0.433**                                                                  No (P\<0.001)
  \-**Vascular Risk** \[Endothelial Function\] \[Hypertension\]                          *AGT-174*       1906150    1q42.2      rs4762 \[9360G\>A, T174M\]                       9360A                           3453    G = 0.873 **A = 0.127**               GG = 0.762 GA = 0.222 **AA = 0.016**                                                                  No (P\< 0.025)
  \-**Vascular Risk** \[Endothelial Function\] \[Hypertension\]                          *AGT-235*       1906150    1q42.2      rs699 \[9543A\>G, M235T\]                        9543G                           3453    A = 0.504 **G = 0.496**               AA = 0.254 AG = 0.500 **GG = 0.246**                                                                  No (P\<0.001)
  \-**Vascular Risk** \[Immune Response\]                                                *IL1B*          147720     2q14        rs1143634 \[3954C\>T\]                           3954T                           930     C = 0.795 **T = 0.205**               CC = 0.632 CT = 0.326 **TT = 0.042**                                                                  No (P\<0.025)
  \-**Vascular Risk** \[Immune Response\]                                                *IL6 -174*      147620     7p21        rs1800795 \[-174G\>C\]                           -174C                           930     G = 0.577 **C = 0.423**               GG = 0.333 GC = 0.489 **CC = 0.179**                                                                  No (P\< 0.001)
  \-**Vascular Risk** \[Immune Response\]                                                *IL6 -573*      147620     7p21        rs1800796 \[-573G\>C\]                           -573C                           930     G = 0.856 **C = 0.144**               GG = 0.733 GC = 0.247 **CC = 0.021**                                                                  No (P\< 0.001)
  \-**Vascular Risk** \[Immune Response\]                                                *IL6R*          147880     1q21        rs8192284 \[1510A\>C\]                           1510C                           930     A = 0.612 **C = 0.388**               AA = 0.375 AC = 0.475 **CC = 0.151**                                                                  Yes (P=0.85-0.9)
  \-**Vascular Risk** \[Immune Response\]                                                *TNFA*          191160     6p21.33     rs1800629 \[-308G\>A\]                           -308A                           929     G = 0.854 **A = 0.146**               GG = 0.729 GA = 0.249 **AA = 0.021**                                                                  Yes (P=0.55-0.6)
  **Panel \[Subpanel\]**                                                                 **Gene**        **OMIM**   **Locus**   **Polymorphism**                                 **Risk SNP**                    **N**   **Allele Freq**                       **Genotype Freq**                                                                                     **H-W**
  \-**Vascular Risk** \[Thrombosis\]                                                     *F2*            17693      11p11.2     rs1799963 \[20210G\>A\]                          20210A                          931     G = 0.983 **A = 0.017**               GG = 0.966 GA = 0.033 **AA = 0.0002**                                                                 Yes (P=0.6-0.65)
  \-**Vascular Risk** \[Thrombosis\]                                                     *F5*            227400     1q24.2      rs6025 \[1691G\>A\]                              1691A                           932     G = 0.991 **A = 0.009**               GG = 0.982 GA = 0.018 **AA = 0.00008**                                                                Yes (P=0.75-0.8)
  \-**Vascular Risk** \[Thrombosis\]                                                     *MTHFR (A/C)*   607093     1p36.22     rs1801131 \[1298A\>C\]                           1298C                           1004    A = 0.705 **C = 0.295**               AA = 0.497 AC = 0.416 **CC = 0.087**                                                                  Yes (P=0.55-0.6)
  \-**Vascular Risk** \[Thrombosis\]                                                     *MTHFR (C/T)*   607093     1p36.22     rs1801133 \[677C\>T\]                            677T                            2018    C = 0.624 **T = 0.376**               CC = 0.389 CT = 0.469 **TT = 0.141**                                                                  Yes (P=0.7-0.75)
  \-**Neurodegeneration**                                                                *PSEN1*         104311     14q24.2     rs165932 \[+16G\>T\]                             +16G                            2087    T = 0.429 **G = 0.571**               TT = 0.184 TG = 0.490 **GG = 0.326**                                                                  No (P\< 0.001)
  \-**Neurodegeneration**                                                                *A2M*           103950     12p13.31    rs669 \[2998G\>A\]                               2998G                           2000    A = 0.694 **G = 0.306**               AA = 0.482 AG = 0.425 **GG = 0.094**                                                                  Yes (P=0.05-0.1)

*A2M*: alpha-2-macroglobulin; *ACE*: angiotensin I converting enzyme; *AGT*: angiotensinogen; *APOB*: apolipoprotein B; *APOC3*: apolipoprotein CIII; *APOE*: apolipoprotein E; *CETP*: cholesteryl ester transfer protein plasma; *F2*: coagulation factor II; *F5*: coagulation factor V; *IL1B*: Interleukin 1 beta; *IL6*: Interleukin 6; *IL6R*: Interleukin 6 receptor; *LPL*: lipoprotein lipase; *MTHFR*: methylenetetrahydrofolate reductase (NAD(P)H); *NOS3*: nitric oxide synthase 3; *PRNP*: prion protein; *PSEN1*: Presenilin 1; *TNFA*: tumor necrosis factor A. H-W: Hardy-Weinberg equilibrium. Significant deviation from H-W equilibrium (χ^2^, P\<0.05).

###### 

Comparative distribution of genotype frequencies of gene polymorphisms associated with obesity, vascular/cardiovascular risk, and neurodegeneration in our study and other European populations \[48, 49\].

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **\_\_**        **\_\_**   **Genotype Frequencies**                                                                                                                                              
  --------------- ---------- -------------------------- --------------------------- --------------------------- ------------------------- --------------------------- ---------------------------- ---------------------------
  ***A2M***       AA AG GG   0.482 0.425 0.093          0.465\                      0.625\                      0.333 0.465 0.202         0.428\                      0.551\                       0.504 0.421 0.075
                                                        0.446\                      0.250\                                                0.495\                      0.402\                       
                                                        0.089                       0.125                                                 0.077                       0.047                        

                                                        **χ2 = 0.07 P\>0.95**       **χ2 = 7.13 P\<0.05**       **χ2 = 18.31 P\<0.001**   **χ2 = 0.97 P\>0.65**       **χ2 = 3.46 P\>0.2**         **χ2 = 0.44 P=0.8**

  ***ACE***       CC CT TT   0.117 0.450 0.433          \--                         0.149\                      0.152 0.515 0.333         0.263 0.473 0.264           0.178\                       0.121 0.43 0.449
                                                                                    0.474\                                                                            0.486\                       
                                                                                    0.376                                                                             0.336                        

                                                        \--                         **χ2 = 5.78 P\>0.05**       **χ2 = 11.22 P\<0.005**   **χ2 = 16.43 P\<0.001**     **χ2 = 9.49 P\<0.01**        **χ2 = 3.29 P\>0.15**

  ***AGT-174***   GG GA AA   0.762 0.222 0.016          0.791\                      0.783\                      0.627 0.343 0.030         0.791 0.209 0.000           0.803\                       0.757 0.215 0.028
                                                        0.200\                      0.217\                                                                            0.178\                       
                                                        0.009                       0.000                                                                             0.019                        

                                                        **χ2 = 1.97 P\>0.4**        **χ2 = 1.08 P\>0.55**       **χ2 = 10.59 P=0.005**    **χ2 = 2.07 P\>0.35**       **χ2 = 0.75 P\>0.65**        **χ2 = 0.19 P\>0.9**

  ***AGT-235***   AA AG GG   0.254 0.500 0.246          0.371\                      0.218\                      0.303 0.535 0.162         0.384\                      0.355 0.439 0.206            0.365 0.439 0.196
                                                        0.434\                      0.652\                                                0.484 0.132                                              
                                                        0.195                       0.130                                                                                                          

                                                        **χ2 = 39.89 P\<0.001**     **χ2 = 1.21 P\>0.5**        **χ2 = 6.28 P\<0.05**     **χ2 = 18.5 P\<0.001**      **χ2 = 17.04 P\<0.001**      **χ2 = 18.55 P\<0.001**

  ***APOC3***     CC CG GG   0.821 0.170 0.009          1.000\                      0.841\                      0.727 0.263 0.010         0.770\                      0.766\                       0.757 0.224 0.019
                                                        0.000\                      0.159\                                                0.220\                      0.206 0.028                  
                                                        0.000                       0.000                                                 0.010                                                    

                                                        **χ^2^ = 46.00 P\<0.001**   **χ2 = 0.63 P\>0.7**        **χ2 = 6.43 P\<0.05**     **χ2 = 2.03 P\>0.35**       **χ2 = 3.05 P\>0.2**         **χ2 = 3.00 P\>0.2**

  ***IL1B***      CC CT TT   0.632 0.326 0.042          0.159\                      0.583\                      0.566 0.394 0.040         0.450 0.473 0.077           0.617 0.374 0.009            0.533 0.402 0.065
                                                        0.310\                      0.250\                                                                                                         
                                                        0.531                       0.167                                                                                                          

                                                        **χ2 = 359.5 P\<0.001**     **χ2 = 10.55 P\<0.01**      **χ2 = 3.61 P\>0.15**     **χ2 = 13.41 P\<0.0025**    **χ2 = 5.62 P\>0.05**        **χ2 = 5.15 P\>0.05**

  ***IL6-174***   GG GC CC   0.333 0.489 0.179          0.247\                      0.208\                      0.313 0.465 0.222         0.373 0.429 0.198           0.411 0.477 0.112            0.420 0.449 0.131
                                                        0.434\                      0.542\                                                                                                         
                                                        0.319                       0.250                                                                                                          

                                                        **χ2 = 17.99 P\<0.001**     **χ2 = 4.24 P\>0.1**        **χ2 = 0.7 P\>0.65**      **χ2 = 0.17 P\>0.95**       **χ2 = 4.9 P\>0.1**          **χ2 = 3.52 P\>0.15**

  ***IL6-573***   GG GC CC   0.733 0.247 0.021          0.914\                      0.990\                      0.899 0.101 0.000         0.923 0.077 0.000           0.897 0.103 0.000            0.897 0.103 0.000
                                                        0.086 0.000                 0.010 0.000                                                                                                    

                                                        **χ2= 26.62 P\<0.001**      **χ2 = 13.01 P\<0.0025**    **χ2 = 10.41 P\<0.01**    **χ2 = 12.41 P\<0.025**     **χ2 = 10.99 P\<0.005**      **χ2 = 10.99 P\<0.005**

  ***LPL***       CC CG GG   0.724 0.254 0.022          0.766\                      0.545\                      0.788 0.192 0.020         0.791 0.187 0.022           0.701 0.271 0.028            0.776 0.196 0.028
                                                        0.217\                      0.364\                                                                                                         
                                                        0.017                       0.091                                                                                                          

                                                        **χ2 = 4.02 P\>0.1**        **χ2 = 9.87 P\<0.01**       **χ2 = 1.67 P\>0.4**      **χ2 = 1.43 P\>0.45**       **χ2 = 2.97 P\>0.2**         **χ2 = 0.85 P\>0.65**

  ***PSEN1***     TT TG GG   0.184 0.490 0.326          0.319\                      0.435\                      0.222 0.505 0.273         0.285 0.506 0.209           0.261 0.533 0.206            0.336 0.486 0.178
                                                        0.504 0.177                 0.391 0.174                                                                                                    

                                                        **χ^2^ = 54.47 P\<0.001**   **χ^2^ = 34.27 P\<0.001**   **χ^2^ = 6.05 P\<0.05**   **χ^2^ = 16.06 P\<0.001**   **χ^2^ = 13.59 P\<0.0025**   **χ^2^ = 33.73 P\<0.001**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*A2M*: alpha-2-macroglobulin; *ACE*: angiotensin I converting enzyme; *AGT*: angiotensinogen; *APOC3*: apolipoprotein CIII; *CETP*: cholesteryl ester transfer protein plasma; *IL1B*: Interleukin 1 beta; *IL6*: Interleukin 6; *LPL*: lipoprotein lipase; *PSEN1*: Presenilin 1.

Populations: 1301 healthy individuals with a Northern and Western European ancestry extracted from the HapMap-CEU study (N-W Europeans) \[[@r48]\]; 23 healthy individuals from France and Utah residents with European ancestry (Western Europeans) \[[@r48]\]; and 99, 91, 107, and 107 healthy individuals from Finland, Britain, Spain, and Italy, respectively, extracted from the 1000 Genomes database \[[@r49]\].

###### 

Genotype frequencies of *APOE* polymorphisms in our population and different Spanish populations of healthy individuals (Control) or individuals with Alzheimer's disease (AD).

  **\_\_**     **\_\_**                                **Genotype Frequencies**              **\_\_**                                                                                                                                                                                                                                                                  
  ------------ --------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- --------------------------------------
  ***APOE***   *ε-2/2 ε-4/4 ε-3/3 ε-2/3 ε-2/4 ε-3/4*   0.002 0.022 0.668 0.079 0.014 0.212   0.005 0.005 0.780 0.100 0.000 0.120   0.002 0.008 0.732 0.089 0.009 0.155   0.005 0.010 0.672 0.116 0.014 0.164   0.002 0.011 0.731 0.070 0.009 0.178   0.000 0.010 0.830 0.027 0.005 0.128   0.000 0.080 0.580 0.020 0.000 0.320   0.001 0.092 0.531 0.051 0.020 0.296   \[51, 52, 54, 56, 58, 61\] \[63-67\]
  **\_\_**     **\_\_**                                **\_\_**                              **χ^2^ = 23.37 P\<0.001**             **χ^2^ = 34.43 P\<0.001**             **χ^2^ = 16.71 P\<0.01**              **χ^2^ = 12.23 P\<0.01**              **χ^2^ = 22.44 P\<0.001**             **χ^2^ = 27.99 P\<0.001**             **χ^2^ = 29.43 P\<0.001**             **\_\_**

Spanish groups description: control (healthy) individuals from a broad distribution of Spanish regions (n=1286), and other groups from specific regions, such as Asturias (n=250), Barcelona (n=478), and Navarra (n=188). Table also includes two Spanish groups with individuals diagnosed with Alzheimer Disease from Navarra (n=98) and Asturias (n=120).
